CXCL5 antibody (PE)

Catalog No. ABIN2662704

This Mouse Monoclonal antibody specifically detects CXCL5 in FACS. It exhibits reactivity toward Human.

Quick Overview for CXCL5 antibody (PE) (ABIN2662704)

Target: CXCL5 (Chemokine (C-X-C Motif) Ligand 5 (CXCL5))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CXCL5 antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Clone: J111B7

Product Details anti-CXCL5 Antibody (PE)

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CXCL5

Target: CXCL5 (Chemokine (C-X-C Motif) Ligand 5 (CXCL5))

Alternative Name: CXCL5

Background: CXCL5, also known as ENA-78, is a 11.9 kD chemokine and belongs to the intercrine alpha, CXC chemokine family. It is expressed by monocytes and eosinophils in response to IL-1 and TNFα. CXCL5 can interact with CXCR2 and activate neutrophils and induce their migration. In vitro neutrophil chemotactic activity of CXCL5 is three fold higher. IFNγ suppresses expression of CXCL5. NFκB alone is sufficient to induce CXCL5 in contrast to IL-8, which requires both NFκB and C/EBP. Two forms are produced by N terminal proteolytic cleavage, ENA78 (8-78) and ENA 78 (9-78), and these isoforms exhibit higher chemotactic activity. Increased intra-hepatic levels of CXCL5 have been reported in patients with chronic liver disease.

Pathways: Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity